Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ace Clinical Research Group

Neither a doctor nor a teaching hospital

Research payments

$1,502,020

779 payments

Through program year 2025, Ace Clinical Research Group is reported as receiving $1,502,020 in research payments, across 779 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $140,751 10
2024 Research $56,117 3
2023 Research $208,533 21
2022 Research $192,110 269
2021 Research $197,318 229
2020 Research $247,766 173
2019 Research $459,425 74

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novo Nordisk AS $861,333 723 payments
  2. AstraZeneca Pharmaceuticals LP $251,982 18 payments
  3. GlaxoSmithKline, LLC. $149,762 4 payments
  4. AstraZeneca UK Limited $54,699 1 payment
  5. Shire North American Group Inc $43,306 8 payments
  6. AstraZeneca AB $40,125 4 payments
  7. Insmed, Inc. $38,350 14 payments
  8. Shionogi Inc $28,744 1 payment
  9. Novartis Pharmaceuticals Corporation $14,735 1 payment
  10. Takeda Pharmaceuticals U.S.A., Inc. $9,736 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Ex9536-4388 $829,626 708 payments
  2. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $155,709 2 payments
  3. A Phase IV, 12-Week, Randomised, Double-Blind, Triple Dummy Study to C $149,762 4 payments
  4. A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure with Left Ventricular Ejection Fraction (LVEF) Below 55 percent and Chronic Kidney Disease $54,699 1 payment
  5. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Shp647 As Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis Figaro UC 301 $41,806 7 payments
  6. A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. $40,125 4 payments
  7. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $32,420 9 payments
  8. Nn9535-4533 $31,708 15 payments
  9. A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) $29,733 5 payments
  10. Study of S-033188 Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications CAPSTONE 2 $28,744 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record